Dianthus Therapeutics, Inc. (DNTH) is in Healthcare, Biotechnology, based in United States, listed on NasdaqCM. Market cap 4.51B USD. 52-week range 32.22 to 117.88 USD. Data as of 2026-10-09.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while ...